Table 3.

Baseline patient clinical characteristics by pre-ablation OAC

OAC before ablation	Warfarin	Aspirin		None		Dabigatran		Rivaroxaban
Number of ablations	1113	472		136		426		187
LA size (cm)	4.44 ± 0.66	4.01 ± 0.62	<0.0005*	4.04 ± 0.74	<0.0005*	4.36 ± 0.63	=0.031*	4.34 ± 0.84	=0.123
Age (years)	64.5 ± 9.5	60.6 ± 9.6	<0 .0005*	58.4 ± 11.8	<0.0005*	64.6 ± 8.1	<0.848	65.8 ± 9.6	=0.084
Gender female	28.9%	29.4%	=0.856	33.1%	=0.136	27.5%	=0.571	30.5%	=0.728
Duration of AF (years)	6.6 ± 7.7	6.7 ± 6.9	=0.808	5.8 ± 6.4	=0.181	5.8 ± 7.2	=0.064	6.4 ± 7.0	=0.739
# Drugs failed	1.36 ± 1.12	1.13 ± 0.98	<0.0005*	1.13 ± 0.86	=0.004*	1.32 ± 1.09	=0.528	1.18 ± 0.96	=0.021*
CHADS2 score	1.12 ± 1.05	0.61 ± 0.81	<0.0005*	0.58 ± 0.84	<0.0005*	1.28 ± 1.07	=0.0008	1.55 + 1.04	<0.0005*
CHA2DS2-VASC score	1.98 ± 1.44	1.26 ± 1.18	<0.0005*	1.24 ± 1.20	<0.0005*	2.13 ± 1.45	=0.068	2.48 + 1.46	<0.0005*
Hypertension	54.8%	38.3%	<0.0005*	34.6%	<0.0005*	63.3%	=0.003*	67.4%	=0.001*
Diabetes	11.6%	4.2%	<0.0005*	4.4%	=0.012*	16.0%	=0.026*	16.0%	=0.09
BMI	30.1 ± 5.4	28.8 ± 4.9	<0.0005*	27.9 ± 5.2	<0.0005*	29.9 ± 6.1	=0.531	29.3 ± 5.4	=0.061
Paroxysmal AF	21.7%	48.1%	<0.0005*	48.9%	<0.0005*	21.7%	=0.944	26.5%	=0.189
Persistent AF	56.8%	46.5%	<0.0005*	45.9%	=0.017*	64.1%	=0.013*	63.5%	=0.0885
Long-standing AF	21.5%	5.1%	<0.0005*	5.2%	<0.0005*	14.2%	=0.002*	9.9%	=0.001*
Prior cardioversion	55.9%	27.3%	<0.0005*	30.9%	<0.0005*	57.0%	=0.688	50.8%	=0.204
Coronary artery disease	16.6%	11.2%	=0.007*	8.8%	=0.024*	16.2%	=0.878	15.6%	=0.596
Dilated cardiomyopathy	10.8%	4.2%	<0.0005*	2.9%	=0.003*	15.0%	=0.023*	8.0%	=0.30
Prior stroke/TIA	10.3%	1.9%	<0.0005*	2.3%	=0.002*	9.1%	=0.452	6.4%	0.087

AF, atrial fibrillation; TIA, transient ischaemic attack; OAC, oral anticoagulant.

The P values compare each clinical characteristic for each non-warfarin OAC with the patients on warfarin.

*Statistically significant compared with the warfarin group.